Home>>Signaling Pathways>> Proteases>> ACE>>Resorcinolnaphthalein
Resorcinolnaphthalein Catalog No.GC11560

ACE2 activator

Size Price Stock Qty
5mg
$20.00
In stock
10mg
$37.00
In stock
50mg
$159.00
In stock
100mg
$277.00
In stock

Customer Review

Based on customer reviews.

Tel: (626) 353-8530 Email: sales@glpbio.com

Sample solution is provided at 25 µL, 10mM.

Quality Control

Quality Control & SDS

View current batch:

Chemical Properties

Cas No. 41307-63-5 SDF
Synonyms NSC 354317
Chemical Name 3',6'-dihydroxy-spiro[1H,3H-naphtho[1,8-cd]pyran-1,9'-[9H]xanthen-3-one
Canonical SMILES Oc1ccc2c(c1)Oc1cc(O)ccc1C12OC(=O)c2cccc3cccc1c23
Formula C24H14O5 M.Wt 382.4
Solubility ≤20mg/ml in ethanol;20mg/ml in DMSO;20mg/ml in dimethyl formamide Storage Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
  • Molarity Calculator

  • Dilution Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
**When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / CoA (available online).

Calculate

Background

Resorcinolnaphthalein is an Angiotensin-converting enzyme 2 (ACE2) activator [1].

Angiotensin-converting enzyme 2 (ACE2) has been involved in hydrolyzing angiotensin II and opposing its actions, and plays a protective role in the pathogenesis of pulmonary arterial hypertension (PAH) [2]. Targeted disruption of ACE2 in mice results in a severe cardiac contractility defect, increased angiotensin II levels, and upregulation of hypoxia-induced genes in the heart [2].

In vitro: Resorcinolnaphthalein enhanced ACE2 activity in a dose-dependent manner [1].

In vivo: Resorcinolnaphthalein caused significant activation of ACE2 in both normal and diseased rats in 7 days after treatment. Treatment with resorcinolnaphthalein prevented high PAP, right ventricular hypertrophy and neointimal formation. Resorcinolnaphthalein caused an improved endothelia-dependent vasorelaxation and decreased in proinflammatory cytokines, such as TNF-α, MCp-1, IL-6, and increased in anti-inflammatory cytokine IL-10 in the early stage of the pathogenesis [3]. Resorcinolnaphthalein can specifically and effectively enhanced ACE2 activity in rats [4]. ACE2 activation by resorcinolnaphthalein showed effects on pulmonary endothelial dysfunction and neointimal formation during the development of severe PAH in rats [4].

References:
[1] Prada J A H, Ferreira A J, Katovich M J, et al.  Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents[J]. Hypertension, 2008, 51(5): 1312-1317.
[2] Crackower M A, Sarao R, Oudit G Y, et al.  Angiotensin-converting enzyme 2 is an essential regulator of heart function[J]. Nature, 2002, 417(6891): 822-828.
[3] Haber P K, Ye M, Wysocki J, et al.  Angiotensin-converting enzyme 2–independent action of presumed angiotensin-converting enzyme 2 activatorsNovelty and significance[J]. Hypertension, 2014, 63(4): 774-782.
[4] Li G, Liu Y, Zhu Y, et al.  ACE2 activation confers endothelial protection and attenuates neointimal lesions in prevention of severe pulmonary arterial hypertension in rats[J]. Lung, 2013, 191(4): 327-336.